Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Cardiovasc. Med.

Sec. Intensive Care Cardiovascular Medicine

Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1663933

Clinical Outcomes and Mortality Risk of In-Hospital Cardiac Arrest in Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock

Provisionally accepted
Jing  ZhangJing Zhang1Chengcheng  ShaoChengcheng Shao1Jiajia  ZhuJiajia Zhu2Jiang  LiJiang Li1Liying  ChenLiying Chen3*
  • 1Cardiac Critical Care Center Ward I, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
  • 2Cardiac Critical Care Center Ward Ⅱ, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
  • 3Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China

The final, formatted version of the article will be published soon.

Background: This study investigated the clinical characteristics of in-hospital cardiac arrest (IHCA) in patients with acute myocardial infarction (AMI) complicated by cardiogenic shock and assessed the related in-hospital and post-discharge mortality. Methods: This study included 148 patients with AMI complicated by cardiogenic shock who were admitted to the Cardiac Critical Care Center, Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University between September 1, 2021 and July 31, 2024. Study participants were divided into two groups according to the occurrence of IHCA (IHCA group, n=62 and control group, n=86). The primary endpoint was in-hospital mortality, whereas secondary endpoints included in-hospital complications (e.g., ischemic stroke, hemorrhagic stroke, gastrointestinal bleeding, and lower limb ischemia), 30-day post-discharge mortality, and 1-year post-discharge mortality. The association between IHCA and in-hospital mortality was assessed by Cox regression analysis, and post-discharge mortality risks were evaluated by modified Poisson regression analysis. Results: IHCA was associated with significantly higher in-hospital mortality (61.3% vs. 29.8%, P<0.001), 30-day mortality (67.7% vs. 39.3%, P=0.001), and 1-year mortality (71.0% vs. 40.5%, P=0.001) compared with the control group. Cox regression analysis showed that IHCA increased the risk of in-hospital mortality (hazard ratio [HR] 2.064, 95% confidence interval [CI] 1.180–3.609, P=0.011). The relative risks of death within 30 days and 1 year post-discharge were 1.606 (95% CI 1.172–2.201, P=0.003) and 1.644 (95% CI 1.216–2.222, P=0.001), respectively. IHCA patients with non-reversible cardiac arrest had a higher 30-day mortality risk (relative risk [RR] 1.599, 95% CI 1.118–2.286, P=0.010) than those with reversible cardiac arrest, although no significant difference was observed in the risk of 1-year mortality (RR 1.369, 95% CI 0.975–1.922, P=0.070). Conclusions: IHCA increases in-hospital, 30-day, and 1-year mortality risks in patients with AMI complicated by cardiogenic shock. Non-reversible cardiac arrest notably increases the risk of death within 30 days post-discharge.

Keywords: Cardiogenic shock, In-hospital cardiac arrest, reversible cardiac arrest, non-reversible cardiac arrest, acute myocardial infarction

Received: 11 Jul 2025; Accepted: 20 Oct 2025.

Copyright: © 2025 Zhang, Shao, Zhu, Li and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Liying Chen, 13501203375@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.